Next Sunday February 4th, coinciding with World Cancer Day, VHIO launches the Cancer 360 podcast, a series of 8 chapters…
featured news
On January 25-26, 2024, in Berlin, Germany, the JOIN4ATMP project held its Kick-off meeting, an initiative created to map, join…
“la Caixa” Foundation has subsidized a new transversal platform for next generation single-cell sequencing: UNderstanding cancer through sIngle cell seQUEncing:…
Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…
Results of the multi-center, randomized, comparator-controlled phase III NETTER-2 trial show that first-line treatment with radioligand therapy 177LU-DOTATATE in combination…
The Vall d’Hebron University Hospital Accredited Health Institute (ISS-IR-HUVH) has been one of those selected for the Fortalece -Salud program…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
Led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Experimental Hematology Group and the Advanced Therapies Program of…
Published in the journal ESMO Gastrointestinal Oncology, results of a VHIO-led retrospective and multicenter study show that 3.4% of pancreatic…
